Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.

The nano-carrier makes etoposide safer and more effective against lung cancer.

A patient with advanced kidney cancer and no hepatitis C developed skin inflammation due to a drug called interferon alpha-2a.

Sorafenib can cause a unique skin reaction.

Tranilast successfully treated a man's skin sarcoidosis when other treatments failed.

Ruxolitinib may help treat hair loss by reducing inflammation, promoting hair growth signals, and protecting hair follicle immunity.

Deuruxolitinib significantly improves hair satisfaction in severe alopecia areata patients.

Topical ruxolitinib cream may help treat frontal fibrosing alopecia.

PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.

Trastuzumab deruxtecan is effective for advanced breast cancer but has side effects like nausea and fatigue.

The TCL1 transgenic mouse model is useful for understanding human B-cell leukemia and testing new treatments.

AZD6244 treatment causes skin aging effects by depleting skin stem cells.

An HIV patient's complete hair loss was reversed after switching from lopinavir/ritonavir to nelfinavir.

JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.

Lasers can help reduce skin side effects from cancer treatment.

Experts agree on how to manage sugar levels and skin reactions in patients taking the cancer drug alpelisib.

Tofacitinib might be used to treat hair loss.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

Tyrosine kinase inhibitors for endocrine tumors often cause skin issues, requiring early management and treatment adjustments.

Combining gemcitabine with paclitaxel is more effective than with pemetrexed for advanced lung cancer.

Talazoparib is more effective than standard chemotherapy for advanced breast cancer with BRCA mutations.

EGFR inhibitors in breast cancer treatment can cause serious skin issues affecting patient quality of life.

Ruxolitinib helped a patient with alopecia areata regrow hair.

Rituximab effectively treated a woman's bone lymphoma that was resistant to other treatments.

Targeting androgen receptor signaling may improve acute myeloid leukemia treatment.

JAK inhibitors can be safely used in alopecia areata patients with latent hepatitis B or tuberculosis, with proper monitoring.

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

Abrocitinib may effectively treat stubborn alopecia universalis.

The guidelines help doctors manage skin problems from certain cancer treatments to improve patients' lives.